



FluMist Quadrivalent

**Live Attenuated Quadravalent Influenza Vaccine (LAIV4) – FluMist Quadrivalent,**

Currently, LAIV4 is an option for vaccination of healthy, nonpregnant persons aged 2–49 years, including healthcare providers and other close contacts of high-risk persons. No preference is expressed for LAIV or IIV for any person aged 2 through 49 years for whom either vaccine is appropriate. An age-appropriate formulation of vaccine should be used.

**Contraindications to LAIV4:**

LAIV should not be used in the following populations:

- Persons with contraindications listed in the package insert:
  - Children aged 2 through 17 years who are receiving aspirin or aspirin-containing products;
  - Persons who have experienced severe allergic reactions to the vaccine or any of its components, or to a previous dose of any influenza vaccine;
- Pregnant women
- Immunocompromised persons
- Persons with a history of egg allergy
- Children aged 2 through 4 years who have asthma or who have had a wheezing episode noted in the medical record within the past 12 months, or for whom parents report that a health care provider stated that they had wheezing or asthma with the last 12 months.
- Persons who have taken influenza antiviral medications within the previous 48 hours
- Persons who care for severely immunocompromised persons who require a protective environment should not receive LAIV, or should avoid contact with such persons for 7 days after receipt, given the theoretical risk for transmission of the live attenuated vaccine virus to close contacts.

**Warnings and Precautions**

In addition to the groups for whom LAIV is not recommended above, the “Warnings and Precautions” section of the LAIV package insert indicates that persons of any age with asthma might be at increased risk for wheezing after administration of LAIV. The package insert also notes that the safety of LAIV in persons with underlying medical conditions that might predispose them to complications after wild-type influenza virus infection (for example, chronic pulmonary, cardiovascular [except isolated hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders [including diabetes mellitus]), has not been established. These conditions, in addition to asthma in persons ≥ 5 years, should be considered precautions for the use of LAIV.

Trade Name	Age Group	Dosage	Number of Doses	Route
FluMist Quadrivalent, Intranasal (MedImmune) (no preservatives or latex)	2 years to 49 years*	0.2 mL prefilled single use intranasal spray (0.1 mL per nostril)	<p><b>Age 2 up to 8 years:</b> 1 or 2 (1 month apart) doses depending on vaccination history per ACIP recommendations*</p> <p><b>Age ≥ 9 years:</b> 1 dose</p> <p><b>*Refer to Figure 1 below</b></p>	Intranasal


\*For patients ≥ 9 years old – single dose

\*For children aged 2 years of age up to 8 years

Single dose appropriate for age if history of prior seasonal vaccination. See dosing chart and Figure 1 dosing algorithm below.

Two doses appropriate for age about 4 weeks apart if first ever seasonal vaccine. See dosing chart and Figure 1 dosing algorithm below.

FIGURE 1. Influenza vaccine dosing algorithm for children aged 6 months through 8 years — Advisory Committee on Immunization Practices, United States, 2015–16 influenza season



\* The two doses need not have been received during the same season or consecutive seasons.

† Doses should be administered ≥4 weeks apart.

Patient Name: \_\_\_\_\_

DOB: \_\_\_\_\_  
Or label

Name / MR # / Label